Neurocrine Biosciences Inc vs TAL Education Group American Depositary Shares — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while TAL Education Group American Depositary Shares trades at $12.49 (market cap $6.93B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× TAL Education Group American Depositary Shares's market cap, and TAL Education Group American Depositary Shares is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and TAL Education Group American Depositary Shares for 0 Days on average.
| NBIX | TAL | |
|---|---|---|
Market Cap | $14.36B | $6.93B |
Volume | 1,237,180 | 2,470,140 |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $12.91 |
52-Week Low | $123.10 | $8.95 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $14.37B | $4.46B |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →TAL Education Group provides smart learning solutions in China. Its offerings combine teaching content, technology, and learning services through various online and offline formats.
Read more on TAL →